MRNA is trading at $51.46 (+3.3%) in after-hours, extending the significant intraday rally (which closed at +15.8%) driven by positive five-year follow-up data on its mRNA cancer vaccine (intismeran autogene) developed with Merck.
- The key data showed sustained melanoma recurrence prevention when the vaccine was administered alongside Keytruda.
- The rally received additional momentum from a favorable legal patent victory against Arbutus.
- The overall uptrend was also supported by the company's strong 2026 revenue growth projections.